97 related articles for article (PubMed ID: 29895214)
1. Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences.
Mazzoni F; Petreni P; Perna M; Scotti V; Bongiolatti S; Livi L; Di Costanzo F; Voltolini L
Tumori; 2018 Dec; 104(6):NP5-NP9. PubMed ID: 29895214
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer.
Chiu LC; Hsu PC; Wang CC; Ko HW; Kuo SC; Ju JS; Tung PH; Huang AC; Yang CT
Thorac Cancer; 2024 Mar; 15(7):529-537. PubMed ID: 38279515
[TBL] [Abstract][Full Text] [Related]
3. Hypotension from afatinib in epidermal growth factor receptor-mutated non-small cell lung cancer: a case report and literature review.
Tang Z; Ji X; Zhou G; Chen R; Fen Y; Ding H
Anticancer Drugs; 2022 Jan; 33(1):e840-e841. PubMed ID: 34486535
[TBL] [Abstract][Full Text] [Related]
4. [Progress and Discussion of Perioperative Targeted Therapy in Patients
with EGFR-mutated Resectable Non-small Cell Lung Cancer].
Song P; Cui Y
Zhongguo Fei Ai Za Zhi; 2024 May; 27(5):383-390. PubMed ID: 38880926
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib.
Wu CT; Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
Thorac Cancer; 2023 Sep; 14(25):2548-2557. PubMed ID: 37525557
[TBL] [Abstract][Full Text] [Related]
6. EGFR -mutant non-small cell lung cancer patients harboring CDK4 amplification show favorable response to afatinib: Two case reports.
Zhan S; Cheng B; Liu X; Li J; Bai G; Cai Q; Wang H; Xiang Y; Li C; He J; Liang W
Chin Med J (Engl); 2024 Jun; 137(12):1465-1467. PubMed ID: 38775179
[No Abstract] [Full Text] [Related]
7. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
[TBL] [Abstract][Full Text] [Related]
8. Afatinib Plus Bevacizumab Treatment for a Patient With EGFR S645C-Mutant Non-Small Cell Lung Cancer: A Case Report.
Shen CI; Chang JC; Jain S; Olsen S; Wu CE
JCO Precis Oncol; 2024 Jun; 8():e2400007. PubMed ID: 38838275
[No Abstract] [Full Text] [Related]
9. Atypical mutation of epidermal growth factor receptor in resected stage I non-small-cell lung cancers.
Etienne H; Goudou T; Assouad J
Eur J Cardiothorac Surg; 2024 Jan; 65(1):. PubMed ID: 38145494
[No Abstract] [Full Text] [Related]
10. [Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer
with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review].
Chen C; Yu Y; Huang M
Zhongguo Fei Ai Za Zhi; 2024 May; 27(5):399-404. PubMed ID: 38880928
[TBL] [Abstract][Full Text] [Related]
11. EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines.
Nowaczyk J; Fret K; Kaminska-Winciorek G; Rudnicka L; Czuwara J
Anticancer Drugs; 2023 Sep; 34(8):942-948. PubMed ID: 36708507
[TBL] [Abstract][Full Text] [Related]
12. Afatinib treatment of severe respiratory failure due to malignant lymphangitis in a dialysis patient with squamous cell carcinoma of the lung.
Kanai O; Koizumi M; Ito T; Mio T
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38378591
[TBL] [Abstract][Full Text] [Related]
13. Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era.
Facchinetti F; Jänne PA; Tiseo M
J Thorac Oncol; 2023 Sep; 18(9):1118-1120. PubMed ID: 37599043
[No Abstract] [Full Text] [Related]
14. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in
Abdallah SM; Hirsh V
Curr Oncol; 2018 Jun; 25(Suppl 1):S9-S17. PubMed ID: 29910643
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
Kim Y; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
Cancer Res Treat; 2019 Apr; 51(2):502-509. PubMed ID: 29898592
[TBL] [Abstract][Full Text] [Related]
16. Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.
Niogret J; Coudert B; Boidot R
J Thorac Oncol; 2018 Jul; 13(7):e113. PubMed ID: 29935845
[No Abstract] [Full Text] [Related]
17. Afatinib restrains K-RAS-driven lung tumorigenesis.
Moll HP; Pranz K; Musteanu M; Grabner B; Hruschka N; Mohrherr J; Aigner P; Stiedl P; Brcic L; Laszlo V; Schramek D; Moriggl R; Eferl R; Moldvay J; Dezso K; Lopez-Casas PP; Stoiber D; Hidalgo M; Penninger J; Sibilia M; Győrffy B; Barbacid M; Dome B; Popper H; Casanova E
Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925635
[TBL] [Abstract][Full Text] [Related]
18. EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.
Park SE; Noh JM; Kim YJ; Lee HS; Cho JH; Lim SW; Ahn YC; Pyo H; Choi YL; Han J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Res Treat; 2019 Apr; 51(2):493-501. PubMed ID: 29914238
[TBL] [Abstract][Full Text] [Related]
19. Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer.
Sharma N; Graziano S
Cancer Treat Rev; 2018 Sep; 69():143-151. PubMed ID: 30014952
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
